Trial reportInternational journal of hematology2017
Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms.
Trial report in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02897297 (Observatoire Brestois Des Néoplasies Myéloprolifératives), which is not on this map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observatoire Brestois Des Néoplasies Myéloprolifératives
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.Blood advances · 2021Pooled it
- Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2019Pooled it
- A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.British journal of haematology · 2019Guideline
- Real-world data on direct oral anticoagulants in BCR::ABL1-negative myeloproliferative neoplasms (MPNs): a multicenter retrospective study on behalf of scientific subcommittee on MPNs for Turkish society of hematology.Journal of thrombosis and thrombolysis · 2025Article
- Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs.Current treatment options in oncology · 2023Review
- Polycythemia Vera: Barriers to and Strategies for Optimal Management.Blood and lymphatic cancer : targets and therapy · 2023Review
- Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera.Vascular health and risk management · 2023Review
- Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation.Circulation. Cardiovascular quality and outcomes · 2022Article
- Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies.Journal of thrombosis and thrombolysis · 2022Article
- Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.Current hematologic malignancy reports · 2022Review
- Polycythemia Vera With Atrial Fibrillation: A Case Report and Review of the Literature.Cureus · 2022Article
- Treatment Options in AF Patients with Cancer; Focus on Catheter Ablation.Journal of clinical medicine · 2022Review
- Evidence-Based Minireview: Are DOACs an alternative to vitamin K antagonists for treatment of venous thromboembolism in patients with MPN?Hematology. American Society of Hematology. Education Program · 2021Review
- Platelet Heterogeneity in Myeloproliferative Neoplasms.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
- Thrombophilia testing in the era of direct oral anticoagulants.Clinical medicine (London, England) · 2021Review
- Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists.Research and practice in thrombosis and haemostasis · 2021Article
- Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms.Annals of hematology · 2021Article
- Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Review
- Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps.The oncologist · 2021Article
- From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.Hematology. American Society of Hematology. Education Program · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct oral anticoagulants (DOACs) have been approved to treat and prevent thrombotic events. However, they are not yet labeled for use in patients with active cancers. Myeloproliferative neoplasms (MPNs) are clonal chronic disorders with a high incidence of thrombotic events, for which low-dose aspirin (LDA) is the standard drug treatment. We analyzed efficacy and safety of DOACs prescription in patients treated for MPNs. An MPN database, the OBENE registry, was established at our institution. We collected biological and clinical data from diagnosis to last follow-up for every patient included in this study. Thrombotic and hemorrhagic events and hematologic evolutions were categorized as major events in the database. Of the 760 MPN patients in the OBENE registry, 25 (3.3%) were treated with a DOAC. Median follow-up duration was 2.1 years (0.12-4.3 years). The reasons for prescribing DOACs were atrial fibrillation and thrombotic events for 13 and 12 patients, respectively. We only observed one thrombotic event (4%) and three major hemorrhagic events (12%). A case-control study did not detect a significant difference in thrombotic or hemorrhagic events in patients treated with LDA and DOACs. These preliminary results suggest that DOACs may be highly efficient and safe for use in MPN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.